Document Detail


Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention.
MedLine Citation:
PMID:  19147609     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: The aim of this study was to identify a subset of patients at high risk of bleeding or myocardial infarction from a percutaneous coronary intervention and to investigate whether such high-risk subsets derive preferential benefit from heparin or bivalirudin. METHODS AND RESULTS: This study included 4570 patients with coronary artery disease enrolled in the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment trial and randomized to receive bivalirudin or heparin. Primary outcomes were in-hospital incidence of major bleeding and 30-day incidence of myocardial infarction. Major bleeding, myocardial infarction, and bleeding plus myocardial infarction occurred in 140, 204, and 34 patients, respectively. Older age, female sex, lower body weight, low cholesterol, multi-lesion intervention, complex lesions, and heparin therapy were independent correlates of increased risk of bleeding. Multi-lesion intervention, unstable angina, and lower body weight correlated independently with increased risks of myocardial infarction. Compared with heparin, bivalirudin was associated with a reduction in major bleeding (3.1 vs. 4.6%, P = 0.008), but mostly in low-risk patients. A reduction in the bleeding risk inversely correlated with an increase in the risk of myocardial infarction with bivalirudin (R = -0.61). CONCLUSION: Bivalirudin and unfractionated heparin have a differential effect on risk of bleeding and myocardial infarction across various subsets of patients.
Authors:
Raisuke Iijima; Gjin Ndrepepa; Julinda Mehilli; Robert A Byrne; Stefanie Schulz; Franz-Josef Neumann; Gert Richardt; Peter B Berger; Albert Schömig; Adnan Kastrati
Related Documents :
8043909 - Thrombinogenesis and its pharmacological modulation in atherosclerosis.
11573859 - Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery.
19530369 - The role of low-molecular-weight heparins in the management of unstable angina and non-...
11567679 - Oral glycoprotein iib/iia antagonists for unstable angina--is there still a chance for ...
10709819 - Reduction of blood loss and transfusion requirements after coronary artery bypass graft...
2519899 - Aspirin, platelets and prevention of vascular disease.
10888209 - Predictive value of remnant-like particle cholesterol as an indicator of coronary arter...
15330739 - Atorvastatin versus pravastatin: intensive versus moderate lipid lowering.
3227889 - Dynamics of the interventricular septum and ventricular free walls during regional isch...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-01-15
Journal Detail:
Title:  European heart journal     Volume:  30     ISSN:  1522-9645     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-02-02     Completed Date:  2009-03-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  290-6     Citation Subset:  IM    
Affiliation:
Deutsches Herzzentrum, Technische Universität, Lazarettstr. 36, 80636 Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Angioplasty, Transluminal, Percutaneous Coronary / adverse effects*,  methods
Anticoagulants / adverse effects*,  therapeutic use
Coronary Disease / radiography,  therapy
Double-Blind Method
Female
Hemorrhage / etiology*
Heparin / adverse effects*,  therapeutic use
Hirudins / adverse effects*
Humans
Male
Middle Aged
Myocardial Infarction / etiology*,  prevention & control
Peptide Fragments / adverse effects*,  therapeutic use
Recombinant Proteins / adverse effects,  therapeutic use
Risk Factors
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Hirudins; 0/Peptide Fragments; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ventricular transmural repolarization sequence: its relationship with ventricular relaxation and rol...
Next Document:  Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammator...